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Abstract Epiregulin (EPR), a novel member of epidermal
growth factor (EGF) family, is a ligand for ErbB-1 and
ErbB-4 receptors. The binding a⁄nity of EPR for the receptors
is lower than those of other EGF-family ligands. The solution
structure of EPR was determined using two-dimensional nuclear
magnetic resonance spectroscopy. The secondary structure in
the C-terminal domain of EPR is di¡erent from other EGF-
family ligands because of the lack of hydrogen bonds. The
structural di¡erence in the C-terminal domain may provide an
explanation for the reduced binding a⁄nity of EPR to the ErbB
receptors.
* 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Epiregulin (EPR) is a novel growth-regulating ligand be-
longing to the epidermal growth factor (EGF) family, which
is puri¢ed from conditioned medium of the mouse ¢broblast-
derived tumor cell line NIH3T3/clone T7 [1,2]. Human EPR is
mainly expressed on peripheral blood macrophages, placenta
in normal tissues and epithelial tumor cell lines [3]. EPR ex-
hibits bifunctional regulatory properties : it inhibits the
growth of some epithelial tumor cells and stimulates the
growth of ¢broblasts and various other types of cells [1].
EPR stimulates the proliferation of gastric cells [4] and human
keratinocytes [5,6], and it is a factor a¡ecting pancreatic can-
cer and in£ammatory disease [7,8]. Therefore, EPR plays a
critical role in regulating several biological activities.
EPR consists of 46 amino acid residues, and the amino acid
sequence of EPR exhibited 24^50% amino acid sequence iden-
tity with sequences of other EGF-family ligands [1]. EGF-
family ligands act as a trigger for the signal transmission
system by binding to the receptors [9]. These receptors are
known as ErbB-family receptors, and they consist of four
types: ErbB-1, ErbB-2, ErbB-3 and ErbB-4. EPR binds to
ErbB-1 and ErbB-4 [10^12], and its selectivity for ErbB-family
receptor is similar to that for betacellulin (BTC).
Jones et al. have reported comparisons of binding speci¢c-
ities and a⁄nities of EGF-family ligands for ErbB receptors
[11]. According to their ¢ndings, the binding a⁄nities of EGF,
transforming growth factor-K (TGF-K), BTC, heparin-binding
EGF-like growth factor (HB-EGF), heregulin-K (HRG-K),
and -L for each ErbB receptor are high or moderate. On the
other hand, binding a⁄nities of EPR for ErbB receptors are
weak. EPR shows the weakest a⁄nity for both the homo-
dimer and heterodimer of ErbB receptors.
Among EGF-family ligands, the tertiary structures of EGF
[13], TGF-K [14], the EGF-like domain of HRG-K (HRG-Ke)
[15], the EGF-like domain of BTC (BTCe) [16], and HB-EGF
[17] have been determined using nuclear magnetic resonance
(NMR) spectroscopy or X-ray di¡raction. Despite the pri-
mary sequence diversity, these tertiary structures are very sim-
ilar. All EGF-family ligands are composed of N- and C-ter-
minal domains, each of which has a L-sheet.
The C-terminal domain is suggested to be involved in the
binding of EGF-family ligands to ErbB receptor. For exam-
ple, the substitution of the highly conserved Arg41 and Leu47
of EGF results in a marked reduction in the a⁄nity for the
EGF receptor, suggesting that these residues are essential for
binding to the receptors [18,19]. It has been reported that the
substitution of the C-terminal tail of human TGF-K into hu-
man EGF results in high-a⁄nity binding of human EGF to
the chicken ErbB-1 [20].
In this study we examine the structure of EPR by NMR
spectroscopy and discuss the relation between the binding
a⁄nity and the tertiary structure. The report presented here
may provide crucial information for elucidating the detailed
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mechanisms underlying binding a⁄nity of the EGF-family li-
gand for ErbB-family receptor.
2. Materials and methods
2.1. Sample preparation of EPR
The DNA fragment encoding EPR was inserted into the expression
vector, pET32a (Novagen), and EPR was expressed as a soluble form
of thioredoxin (Trx)-His-tag fusion proteins. The Trx-His-tag-fusion
EPR was expressed in AD494(DE3), which is a Trx reductase-de¢-
cient Escherichia coli strain. The soluble fraction was puri¢ed by His-
tag a⁄nity chromatography using Ni-NTA agarose (Qiagen). The
bu¡er of the protein solution eluted was changed to EKMax reaction
bu¡er (Invitrogen) using a PD-10 column (Amersham Pharmacia Bio-
tech). EKMax (Invitrogen) enzyme was added at a ¢nal ratio of 0.5
units per 1 mg of protein and incubated at 33‡C for 12 h. Finally, the
cleavage products were puri¢ed by reverse-phase high-performance
liquid chromatography. The puri¢ed EPR was identi¢ed by mass
spectrometry (MALDI-TOF MS: Voyager) and N-terminal amino
acid analysis (Shimadzu PPSQ-21). The biological activity of the pu-
ri¢ed EPR was con¢rmed by growth inhibitory activity for A431 [1].
A431 cells were plated in 96-well dishes at a density of 1.5U103 cells/
well in the medium containing 10% fetal bovine serum and incubated
at 37‡C for 24 h. Then, EPR was added at various concentrations
[21]. After 3 days, TetraColor ONE (Seikagaku Corporation), which
is a reagent for modi¢ed MTT assay, was added to each well, and,
after 4 h of incubation, the absorbance at 450 nm was measured.
2.2. 1H NMR spectroscopy
The EPR sample was dissolved at a ¢nal concentration of 1.5 mM
in 300 Wl of either 90% H2O/10% D2O or 100% D2O. The pH was
adjusted to 3.4 to observe amide protons by decreasing the hydrogen^
deuterium (H^D) exchange rates. The NMR experiments were per-
formed on a Bruker DMX-500 spectrometer. The majority of NMR
spectra were recorded at 30‡C, and some experiments were carried out
at 40‡C to resolve ambiguities. Double quantum ¢ltered correlation
spectroscopy (DQF-COSY) [22] spectra were collected at 30‡C. Total
correlation spectroscopy (TOCSY) [23] spectra were obtained at 30‡C
and 40‡C with a mixing time of 80 ms. Nuclear Overhauser enhance-
ment spectroscopy (NOESY) [24] spectra were collected at 30‡C and
40‡C with a mixing time of 100 and 150 ms. The TOCSY and NO-
ESY spectra at 30‡C and pH 7.0 were measured and the 1H resonan-
ces were partially assigned. However, the quality of NMR spectra at
pH 7.0 was not good enough to solve the solution structure of EPR.
All NMR data were processed and analyzed on a LINUX worksta-
tion using NMRpipe1.8 [25] and PIPP 4.3.2 [26] software.
2.3. Structural calculations
The interproton distance restraints were calibrated using nuclear
Overhauser e¡ect (NOE) peak intensities. The P angle restraints
were applied using spin^spin coupling constants 3JNHKH and chemical
shift index (CSI) [27] analysis data. The 3JNHKH coupling constants
were determined from a high digital resolution DQF-COSY spectrum.
Residues with 3JNHKHs 10 Hz were constrained to P=3120T40‡.
When 3JNHKH was not obtained, the P angle was constricted on the
basis of CSI data, i.e. P=360T 30‡ for the residue with CSI= 1. The
Backbone P angle restraints were applied for 33 residues on the basis
of 3JNHKH and ¢ve residues on the basis of CSI. The backbone amide
H^D exchange experiment was performed to identify the hydrogen
bond donors forming secondary structures. Residues for which the
amide proton exchange rates are su⁄ciently slow were identi¢ed in
the NOESY spectrum of a freshly prepared solution of EPR in D2O.
For each donor, its acceptor was determined on the basis of the
preliminary calculated structure. The hydrogen-bonding restraints
were included only in the regions of identi¢ed secondary structure
and set to be 2.00T 0.20 AV for NH^O distances and 3.00T0.30 AV
for N^O distances for regular secondary structures. This information
about the hydrogen bonds was used to calculate the tertiary structure.
During the initial calculation stage, 50 starting structures were calcu-
lated from an extended conformation of EPR using a simulated an-
nealing (SA) protocol in X-PLOR 3.1 [28]. The structural re¢nement
was carried out by starting with the 40 lowest-energy structures of the
previous iteration. The energy-minimized average structure of EPR
was calculated using the modi¢ed SA protocol by starting with the
40 lowest-energy structures of the ¢nal iteration. All structural calcu-
lations were performed on a LINUX workstation. Validation of the
¢nal structures was con¢rmed using PROCHECK-NMR [38]. Rama-
chandran plot analysis showed that all of the residues have backbone
dihedral angles in the allowed regions of the P, i plot. The structures
were displayed using MOLMOL [29].
2.4. Comparison with other EGF-family proteins
To compare the structural properties of EPR with those of other
EGF-family proteins, we used the coordinate data from the Protein
Data Bank (PDB). The secondary and tertiary structures of EPR were
compared with those of human TGF-K (the PDB accession code is
2TGF) [14], mouse EGF (1EGF) [13], HRG-Ke (1HAF) [15], HB-
EGF (1XDT) [17], and human BTCe (1IOX) [16].
2.5. Circular dichroism (CD) spectroscopy
CD spectra of EPR were measured using a JASCO J-805 spectrom-
eter (Japan Spectroscopic Co., Ltd., Tokyo, Japan) with a 1-mm
quartz cell. The protein concentrations for CD measurements were
155 WM. Protein concentrations were determined by absorbance mea-
surements at 280 nm. The temperature of the measuring cell was
maintained at 25‡C by circulating water. Bu¡er solutions contained
250 mM phosphate (pH 6.0 or 7.0) or 250 mM glycine (pH 3.4).
3. Results and discussion
3.1. Chemical shift assignments of EPR
The chemical shift assignment of EPR was carried out using
the sequential assignment procedure [30]. The sequential as-
signment was achieved by a combination of TOCSY and NO-
ESY spectra acquired at 30‡C and 40‡C. The 1H resonance of
all of the main chain atoms, except for the amide proton of
the N-terminal Val1, and most of the side chain atoms of EPR
at pH 3.4 were unambiguously assigned. The assignment of
Table 1
Structural statistics for the family of 40 structures of EPR
Experimental restraints
Intraresidue distances (i3j=0) 297
Sequential distances (Mi3jM=1) 128
Medium-range distances (Mi3jM6 =4) 46
Long-range distances (Mi3jMs 5) 85
Hydrogen bonds 9
Dihedral angles 38
Total 603
Mean RMSDs from idealized covalent geometrya
Bonds (AV ) 0.002T 0.000
Angles (deg) 0.511T 0.011
Impropers (deg) 0.361T 0.014
Mean X-PLOR energies (kcal mol31)
ENOEb 99.77T 2.12
Ecdihb 0.39T 0.09
Ebond 2.18T 0.39
EVDW 21.78T 1.22
Atomic RMSDs (AV )c
Well-de¢ned region (residues 4^44)
Backbone atoms 0.97T 0.25
Heavy atoms 1.51T 0.27
N-terminal domain (residues 4^33)
Backbone atoms 0.90T 0.28
Heavy atoms 1.50T 0.32
C-terminal domain (residues 34^44)
Backbone atoms 0.48T 0.21
Heavy atoms 0.98T 0.26
aIdealized geometry is de¢ned by the CHARMM force ¢eld as im-
plemented within X-PLOR.
bThe ¢nal values of the square-well NOE and dihedral angle poten-
tials were calculated with force constants of 50 and 200 kcal mol31
AV 32, respectively.
cAtomic di¡erences are given as the average di¡erence against the
mean coordinate structure. All statistics are given as meansTS.D.
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1H resonances of EPR at 30‡C and pH 3.4 was deposited in
the BioMagResBank (accession number 5173). Fig. 1 summa-
rizes the sequential NOE connectivities, 3JNHKH, the slowly
exchanging amide protons and the CSI analysis.
3.2. Structural calculation of EPR
The solution structure of EPR at 30‡C and pH 3.4 was
calculated using NMR-derived 603 experimental restraints.
A total of 556 distance restraints were obtained from the
NOESY spectrum. The distance restraints can be subdivided
into 297 intraresidual, 128 sequential, 46 medium-range, and
85 long-range restraints. The 38 dihedral P angle restraints
and nine hydrogen bond restraints were used as additional
restraints for the calculations. Fig. 2A shows the ensemble
of 40 NMR structures of EPR best ¢tted for the backbone
atoms of the converged region (Thr4-Phe44). The root mean
square deviation (RMSD) of the backbone atoms evaluated
for the converged region of the 40 structures against the mean
structure was 0.97T 0.25 AV for the backbone atoms and
1.51T 0.27 AV for all non-hydrogen atoms. The RMSD of
the backbone atoms evaluated for the N-terminal (Thr4-
Glu33) and C-terminal (Val34-Phe44) domains are 0.90T 0.28
and 0.48 T 0.21 AV , respectively (Table 1). The RMSD of the
L-sheet comprised of strand-2 and -3 in the N-terminal do-
main (Gly17-Cys32) is 0.37T 0.11 AV .
Fig. 2B shows a ribbon drawing of the energy-minimized
average structure of EPR. Secondary structures were deter-
mined using the program MOLMOL [29]. EPR is comprised
of three strands (strand-1, -2, and -3 are composed of Thr4-
Lys5, Gly17-Leu22, and Gln27-Cys32, respectively) and one
Fig. 1. Diagram of NOE connectivities between protons of neighboring (dKN and dNN), J-coupling constants (3JNHKH), slowly exchanging amide
protons in D2O, and CSI analysis [27]. The strength of the observed NOE in NOESY spectra at 30‡C is represented by the thickness of the
bars. Residues with 3JNHKHs 10 Hz are indicated by closed circles. The backbone amide protons, which exchange slowly with D2O, are indi-
cated by open circles. The bottom plot represents the CSI analysis [27] for the CKH resonances, where CSI is shown as positive if the CKH res-
onance is s 0.1 ppm down¢eld from its random coil value, negative if 0.1sppm up¢eld, or 0 if within 0.1 ppm of its random coil value [27].
apH 3.4; bpH 7.0; *not determined.
Fig. 2. Tertiary structure of EPR. A: The ensemble of 40 NMR structures of EPR superimposed and ¢tted for the backbone atoms of residues
4^44. B: The ribbon drawing of the minimized average structure of EPR. Sequence numbers of some residues are indicated. These diagrams
were generated using the program MOLMOL [30].
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short helical turn (Ser8-Met10). The L-sheet structure consist-
ing of strand-1, -2, and -3 is arranged in an antiparallel man-
ner. The atomic coordinates for the ¢nal structures of EPR
were deposited in the PDB (PDB accession code is 1K36 for
the 40 ensemble structures and 1K37 for the energy-minimized
average structure).
3.3. The structure of the N-terminal domain of EPR
The comparisons of the secondary and tertiary structures
between EPR and other EGF-family proteins are shown in
Fig. 3A,B. The secondary and tertiary structures of the N-ter-
minal domain of EPR are similar to those of other EGF-
family proteins. Comparing EPR, EGF, TGF-K, BTCe,
Fig. 3. Sequence alignment and comparisons of the secondary structure of EGF-family ligands including EPR (A) and comparisons of tertiary
structures of EGF-family ligands and EPR (B). The numbers in panel A are residue numbers in the amino acid sequence of each protein. The
asterisks indicate the conserved residues of ligands, except for GBP. In the alignment, the blue characters indicate L-sheet regions and the red
characters indicate helical regions. The drawing of EGF-family ligands and GBP was made using atomic coordinates obtained from the PDB,
and the accession codes are 1EGF [13], 2TGF [14], 1HAF [15], 1IOX [16], 1XDT [17], and 1BQF [37] for EGF, TGF-K, HRG-Ke, BTCe, HB-
EGF, and GBP, respectively. The model structures were generated using the program MOLMOL [30].
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HRG-Ke, and HB-EGF, we found a common structural prop-
erty in the L-sheet that consists of strand-2 and -3, corre-
sponding to Gly17-Leu22 and Gln27-Cys32 of EPR, and the
short turn structure between the two strands (Fig. 3A). In
addition, the tertiary structure of this region of EPR is similar
to the corresponding regions of other ligands (Fig. 3B). An-
other interesting similarity between EPR and other EGF-fam-
ily ligands is that EPR, BTCe, and HRG-Ke adopt a helical
turn in this region of Ser8-Met10 in EPR (Fig. 3A). Tertiary
structures of this region are similar to each other among these
three proteins (Fig. 3B). EGF, TGF-K, and HB-EGF do not
form the helical turn in this region. In particular, the struc-
tures in the N-terminal domain are similar between EPR
and BTCe, which are the ligands for ErbB-1 and ErbB-4
[10^12].
3.4. The structure of the C-terminal domain of EPR
Although the overall structure of the N-terminal domain of
EPR is similar to those of other EGF-family ligands, there is a
marked di¡erence in the structure of the C-terminal domain
between EPR and other EGF-family ligands. The C-terminal
portions of EGF, TGF-K, BTCe, HRG-Ke, and HB-EGF
form an antiparallel L-sheet. However, the C-terminal portion
of EPR does not form a complete L-sheet structure (Figs. 2
and 3). Montelione et al. [13] have reported the H^D ex-
change rate of backbone amide protons of EGF. The back-
Fig. 4. A: Comparison of the structure in the C-terminal domain between EPR and EGF. Hydrogen bonds between Ser38 and Thr44 in EGF
are shown by continuous lines with the hydrogen bond lengths. The lengths between backbone NH and O atoms in EPR are shown by dotted
lines. Backbone NH and O atoms are represented by blue and red, respectively. B: Comparison of the hydrogen bond lengths (AV ) in the C-ter-
minal domain among EGF-family ligands. The lengths between backbone NH and O atoms in EPR are shown for comparison.
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bone amide protons of Tyr37, Ser38, Cys42, Gln43 and Thr44 of
EGF exchanged slowly with deuterium in the H^D exchange
experiment and the interstrand NOEs were observed in the
C-terminal L-sheet of EGF [39]. Only one slowly exchanging
amide proton was observed in the C-terminal domain of EPR
in the amide H^D exchange experiment (Fig. 1) and there was
no NOE between two segments (Tyr36-Thr37 and His43-Phe44)
in the C-terminal domain of EPR (data not shown). These
results suggest that conformation in this region of EPR is
not supported by hydrogen bonds and that the lack of hydro-
gen bonds is responsible for the incomplete L-sheet structure
in the C-terminal domain of EPR. However, the C-terminal
domain adopts a L-sheet-like structure according to 3JNHKH
and CSI analysis (Fig. 1). Therefore, EPR slightly di¡ers from
other EGF-like ligands in the conformation of the C-terminal
domain.
Although EPR is a ligand that binds to the homodimer of
ErbB-1 and ErbB-4 and the heterodimer containing ErbB-2,
the binding a⁄nity of EPR is much lower than those of other
EGF-family ligands [1,11,31]. Structural di¡erences between
EPR and other EGF-family ligands may be associated with
the low binding a⁄nity of EPR for the receptors. The impor-
tance of the structure in the C-terminal domain of EGF-fam-
ily ligands has been suggested in several studies [18^20]. The
C-terminal domain includes Arg41, Asp42, and Leu47 of hu-
man EGF, and Arg42 of human TGF-K ; these residues are
responsible for optimal association with the ErbB-1 receptor
[32^35]. Recently, the crystal structure of the extracellular
domains of ErbB-1 bound to EGF has been reported. The
region containing the loop (residues 6^9) and Arg41 of EGF
interacts with site 2 in domain III of ErbB-1, and the C-ter-
minal region around Arg45 of EGF interacts with site 3 in
domain III of ErbB-1 [41]. The crystal structure of the com-
plex of TGF-K and ErbB-1 extracellular domain has also been
determined, showing that a number of residues in the C-ter-
minal domain of TGF-K interact with the extracellular do-
main of ErbB-1 [42]. In addition, the HRG-K and HRG-L
isoforms are identical in the EGF domain sequence up to ¢fth
Cys, and both directly bind ErbB-3 and ErbB-4, although
their binding a⁄nities are signi¢cantly di¡erent. The binding
of HRG-K is 100-fold weaker than that of HRG-L for the
ErbB-3 and ErbB-4 homodimers [11]. An insect cytokine,
growth-blocking peptide (GBP) has an overall fold similar
to the C-terminal domain of EGF, even though GBP lacks
the N-terminal domain [37] (Fig. 3B). A previous study has
shown that GBP directly binds and activates the EGF recep-
tor in keratinocyte cells and enhances cell proliferation of
human keratinocyte cells with a potency almost equivalent
to that of human EGF [36]. Therefore, the C-terminal domain
may play an important role in binding of EGF-like ligands to
ErbB receptors, and so the di¡erence in the ligand^receptor
binding a⁄nity may depend on structural di¡erences in the
C-terminal domain.
The C-terminal domains of EGF, TGF-K, BTCe, HRG-Ke,
and HB-EGF have a short turn and a continuing double-
stranded L-sheet, and GBP has a similar conformation with
the C-terminal domain of EGF. On the other hand, EPR does
not form a complete L-sheet structure in the C-terminal do-
main (Figs. 1^3). Fig. 4 shows the comparison of structures in
the C-terminal domain among EGF-family ligands. In the
C-terminal domain of EGF, hydrogen bonds are formed be-
tween the Ser38 and Thr44 [39] (Fig. 4A). These hydrogen
bonds also exist in the C-terminal domain of TGF-K, HRG-
Ke and BTCe (Fig. 4B). However, the corresponding residues
of EPR, Thr37 and His43, do not form the hydrogen bonds
(Fig. 4A). The incomplete L-sheet structure in the C-terminal
domain of EPR results from the fact that only the amide
proton of Thr37 exchanges slowly in the H^D exchange ex-
periment and the lack of the interstrand NOEs between two
segments (Tyr36-Thr37 and His43-Phe44) in the C-terminal do-
main (Fig. 1). The structures of EGF, TGF-K, HRG-Ke,
BTCe and GBP previously reported were determined by
NMR and these structures, except for TGF-K, were solved
at acidic pH (pH 2.0^4.5) [13^16,37,40]. We analyzed the
NOESY spectrum of EPR at pH 7.0 and con¢rmed that there
was no interstrand NOEs in the C-terminal domain of EPR at
pH 7.0. The far-UV CD spectra show that the conformation
of EPR does not change in the pH range of 3.4^7.0 (Fig. 5).
The far-UV CD mainly re£ects the secondary structure of
proteins and is slightly contributed by aromatic side chains
and disul¢de bonds. The similarity of the structures at pH 3.4
and 7.0 is also evident from the CSI data, which depend on
the secondary structure of proteins [27]. Moreover, a previous
NMR study has shown that the structures of EGF at pH 6.8
and 2.0 are nearly identical except for the region of Asp46-
Arg53 [40]. Therefore, the lack of L-sheet structure in the
C-terminal domain of EPR at pH 3.4 is not due to the low
pH. The structural di¡erence in the C-terminal domain may
provide an explanation for the reduced binding a⁄nity of
EPR to the ErbB receptors.
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